Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.

The activities of ceftazidime-avibactam, ceftolozane-tazobactam, and comparators were evaluated for 733 isolates displaying resistance to broad-spectrum cephalosporins and carrying extended-spectrum β-lactamase (ESBL) genes detected by whole-genome sequencing analysis. Isolates were collected during 2017 in U.S. hospitals. The ESBL producers were 486 , 190 , and 42 isolates and isolates from 3 other species. The most common groups of ESBL-encoding genes were -like (= 491 isolates) and alone (= 168) or plus (= 260), followed by -like (162), which included and (104 and 51 isolates, respectively), and and (48 and 22 isolates, respectively). ESBL producers carried other β-lactamases, including 1 harboring All ESBL-producing isolates were susceptible to ceftazidime-avibactam, and 90.2/83.9% (CLSI/EUCAST breakpoints) were susceptible to ceftolozane-tazobactam. Tigecycline (98.1/95.8% susceptible) and colistin (99.2%) were comparators that displayed the greatest activity against these isolates. Ceftolozane-tazobactam inhibited 91.4/83.9% of isolates carrying -like and 97.5/95.1% of isolates carrying -like, and its activity was more limited against the 91 isolates carrying (66.7/61.1% susceptible). Ceftolozane-tazobactam inhibited 95.5% of the isolates but only 83.0%, 64.3%, and 80.0% of , , and other species harboring ESBL-encoding genes (CLSI breakpoints), respectively. Outer membrane protein sequences for ceftolozane-tazobactam-nonsusceptible isolates did not exhibit significant differences compared to those in genetically related ceftolozane-tazobactam-susceptible isolates. Ceftazidime-avibactam was more active than other agents tested, including ceftolozane-tazobactam, and the activity of this combination was stable regardless of species or ESBL gene carried.